FdaApplication
NDA 216834
Identifiers
- fda_app_no: NDA216834
Properties
| Property | Value |
|---|---|
| applicant_name | UCB INC |
| application_type | NDA |
| approval_date | 2023-10-17 |
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZILBRYSQ | ZILUCOPLAN SODIUM | EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) | SOLUTION;SUBCUTANEOUS |
| ZILBRYSQ | ZILUCOPLAN SODIUM | EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML) | SOLUTION;SUBCUTANEOUS |
| ZILBRYSQ | ZILUCOPLAN SODIUM | EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML) | SOLUTION;SUBCUTANEOUS |
3 products